Sun Pharma to sell 100 percent stake in Japanese arm

Written By : Ruchika Sharma |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2025-01-01T11:00:55+05:30 | Updated On 1 Jan 2025 11:00 AM IST

Sun Pharma to acquire Checkpoint Therapeutics

Mumbai: Sun Pharmaceutical Industries Limited has entered into an agreement with Zaza Industrial Holdings K.K, Japan, under which Sun Pharma has agreed to sell 100% shares held in Sun Pharma Japan Technical Operations Limited, a step-down subsidiary of the Company (through its subsidiary, Sun Pharma Japan Limited).

Consequently, Sun Pharma Japan Technical Operations Limited shall cease to be a subsidiary of the Company. The expected date of completion of sale/disposal will be January 31, 2025.

Turnover of Sun Pharma Japan Technical Operations Limited is less than 0.5% of Sun Pharma’s consolidated turnover for FY 2023- 24.

"Sun Pharma Japan Technical Operations Limited operates a plant in Saitama, Japan, which manufactures products for Sun Pharma Japan Limited. As part of the sale agreement, the plant is contracted to supply products to Sun Pharma until May 2026," the Company stated in a BSE filing.

Medical Dialogues team had earlier reported that Sun Pharma Laboratories had got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct an active Post-Marketing Surveillance (PMS) study with Etifoxine Hydrochloride Capsules 50 mg.

Zaza Industrial Holdings K.K., a company incorporated under the laws of Japan whose registered office is at Toranomon Hills Edomizaka Terrace #1101, 9-1, Toranomon 2- chome, Minato-ku, Tokyo, 105-0001, Japan. It does not belong to Promoter or Promoter Group of Sun Pharma.

Sun Pharma is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult-to-make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs), and Intermediates.

sun pharmasun pharma newsZaza Industrial HoldingsSun Pharma Japan Technical Operations

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751